Pharmaceutical Jieankang announced that recently, the results of phase 2 exploratory clinical trials for cholangiocarcinoma carried out by the company's core product, tengotinib, in the US were published in “The Lancet, Gastroenterology, and Hepatology”. Cholangiocarcinoma is a highly aggressive biliary tract cancer. Its onset is often driven by FGFR2 fusion. Such mutations can be targeted and treated with inhibitors such as pemitinib and fortibatinib. However, drug resistance tends to occur frequently due to the emergence of acquired FGFR2 mutations. In this phase 2, open-label, multicenter study, eligible cholangiocarcinoma patients included patients with FGFR2 fusion and primary or acquired resistance to FGFR inhibitors, or patients with other FGFR gene changes, and FGFR wild-type patients. Tengotinib overcame acquired resistance to FGFR inhibitors in patients with FGFR2 fusion positive cholangiocarcinoma and showed antitumor activity in other cholangiocarcinoma patients with altered FGFR genes.

Pharmaceutical Jieankang announced that recently, the results of phase 2 exploratory clinical trials for cholangiocarcinoma carried out by the company's core product, tengotinib, in the US were published in “The Lancet, Gastroenterology, and Hepatology”. Cholangiocarcinoma is a highly aggressive biliary tract cancer. Its onset is often driven by FGFR2 fusion. Such mutations can be targeted and treated with inhibitors such as pemitinib and fortibatinib. However, drug resistance tends to occur frequently due to the emergence of acquired FGFR2 mutations. In this phase 2, open-label, multicenter study, eligible cholangiocarcinoma patients included patients with FGFR2 fusion and primary or acquired resistance to FGFR inhibitors, or patients with other FGFR gene changes, and FGFR wild-type patients. Tengotinib overcame acquired resistance to FGFR inhibitors in patients with FGFR2 fusion positive cholangiocarcinoma and showed antitumor activity in other cholangiocarcinoma patients with altered FGFR genes.